Phase 3 Clinical Trials With Primary Completion Dates in November 2015
This is a list of Phase 3 trials with primary completion dates in November 2015 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
|Symbol||Company||Primary Completion Date||Phase||NCT ID||Title|
|ALR||Alere Inc.||2015-11-01||Phase 3||NCT02068118||Optimization of the Ambulatory Monitoring for Patients With Heart Failure by Tele-cardiology|
|EBIO||Eleven Biotherapeutics, Inc.||2015-11-01||Phase 3||NCT02492321||A Multi-Center Environmental Study for the Treatment of Moderate to Severe Ocular Allergic Conjunctivitis|
|EVOK||Evoke Pharma, Inc.||2015-11-01||Phase 3||NCT02025751||Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Men With Diabetic Gastroparesis|
|EVOK||Evoke Pharma, Inc.||2015-11-01||Phase 3||NCT02025725||Multicenter Study to Evaluate the Efficacy and Safety of Metoclopramide Nasal Spray in Women With Diabetic Gastroparesis|
|MRNS||Marinus Pharmaceuticals, Inc.||2015-11-01||Phase 3||NCT01963208||Phase 3 Study of Adjunctive Ganaxolone in Adults With Drug-resistant Partial Onset Seizures and Open-label Extension|
|NEOT||Neothetics, Inc.||2015-11-01||Phase 3||NCT02398188||Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat (AbCONTOUR2)|
|NEOT||Neothetics, Inc.||2015-11-01||Phase 3||NCT02397499||Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat|
|SGYP||Synergy Pharmaceuticals, Inc.||2015-11-01||Phase 3||NCT02387359||The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)|
|XBIT||XBiotech Inc.||2015-11-01||Phase 3||NCT02138422||A Phase 3 Study to Evaluate Xilonix as an Anticancer Therapy in Patients With Symptomatic Colorectal Cancer|
|ZFGN||Zafgen, Inc.||2015-11-01||Phase 3||NCT02179151||Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome|